Streetbeat News

Regulatory

AKBA

Akebia Therapeutics has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, according to a formal notice from Nasdaq. The company's stock will continue to be listed and traded on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 9:20 pm

DMAC

Diamedica Therapeutics has amended its protocol in response to the FDA, incorporating a reduced dose for intravenous administration of DM199. The change was disclosed in an 8K filing.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 9:18 pm

DMAC

DiaMedica Therapeutics has filed a complete clinical hold response with the FDA, requesting the lifting of the clinical hold on its Phase 2/3 trial of DM199 for acute ischemic stroke (AIS). The response includes a protocol amendment to reduce the dose and incorporate additional measures to reduce the risk of severe hypotension.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 9:17 pm

BLTE

Belite Bio Inc has filed for a mixed shelf offering of up to $300 million, according to a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 9:09 pm

MVST

Microvast shares are trading lower after the US Energy Department cancelled contract negotiations for a $200 million award for the company.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 8:57 pm

MVST

The US Energy Department has canceled contract negotiations on a $200 million award for Microvast Holdings, according to a person familiar with the matter.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 8:54 pm

FXLV

F45 Training Holdings Inc. has received a notice of non-compliance from the NYSE due to its trading share price falling below the required minimum. The company has 6 months to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 8:37 pm

RMED

Ra Medical Systems announced a delay in filing its 10-Q report, citing the need for additional time to finalize financial statements and complete the review process.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 8:34 pm

SPY

Treasury Secretary Yellen warns that debt-limit measures could run out as soon as June 1, potentially impacting the US economy and financial markets.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 8:20 pm

ICPT

FDA's Gastrointestinal Drugs Advisory Committee voted against the benefits of Intercept Pharmaceutical's Ocaliva 25 mg for NASH patients with stage 2 or 3 fibrosis. HC Wainwright downgraded the stock to Sell from Neutral, citing potential commercial failure and competition from other drugs.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 8:20 pm